pubmed http://www.fondation-arthritis.org http://www.bio-therapy.net http://www.das-score ,
Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future, Arthritis Res Ther, vol.13, issue.1, p.4, 2011. ,
Biological therapies in the spondyloarthritides--the current state, Rheumatology, vol.43, issue.9, pp.1072-84, 2004. ,
DOI : 10.1093/rheumatology/keh205
Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with serratia marcescens polysaccharide, and induced tolerance, J Nat Cancer Inst, vol.29, pp.1169-75, 1962. ,
An endotoxin-induced serum factor that causes necrosis of tumors., Proceedings of the National Academy of Sciences, vol.72, issue.9, pp.3666-70, 1975. ,
DOI : 10.1073/pnas.72.9.3666
Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin, Nature, vol.249, issue.5996, pp.724-733, 1984. ,
DOI : 10.1038/312724a0
URL : http://hdl.handle.net/11858/00-001M-0000-0019-AF84-E
Human tumor necrosis factor. Production, purification, and characterization, J Biol Chem, vol.264, pp.17595-605, 1985. ,
Precursor structures and structure-function analysis of TNF and lymphotoxin, Immunol Ser, vol.56, pp.79-92, 1992. ,
A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF, Cell, vol.53, issue.1, pp.45-53, 1988. ,
DOI : 10.1016/0092-8674(88)90486-2
Efficiency of recombinant human TNF in human cancer therapy, Cancer Immun, vol.6, p.6, 2006. ,
A new cluster of genes within the human major histocompatibility complex, Science, vol.243, issue.4888, pp.214-221, 1989. ,
DOI : 10.1126/science.2911734
Genetic Polymorphisms in Sepsis and Septic Shock, Chest, vol.124, issue.3, pp.1103-1118, 2003. ,
DOI : 10.1378/chest.124.3.1103
Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages, J Immunol, vol.138, pp.957-62, 1987. ,
Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes, Journal of Experimental Medicine, vol.165, issue.6, pp.1581-94, 1987. ,
DOI : 10.1084/jem.165.6.1581
Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus., Proceedings of the National Academy of Sciences, vol.86, issue.16, pp.6348-52, 1989. ,
DOI : 10.1073/pnas.86.16.6348
Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells, Am J Pathol, vol.124, pp.179-85, 1986. ,
Human vascular smooth muscle cells. Target for and source of tumor necrosis factor, J Immunol, vol.142, pp.100-109, 1989. ,
A conserved AU sequence from the 3??? untranslated region of GM-CSF mRNA mediates selective mRNA degradation, Cell, vol.46, issue.5, pp.659-67, 1986. ,
DOI : 10.1016/0092-8674(86)90341-7
Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor, Cell, vol.61, issue.2, pp.351-360, 1990. ,
DOI : 10.1016/0092-8674(90)90815-V
Decreased sensitivity to tumour-necrosis factor but normal T-cell
development in TNF receptor-2-deficient mice, Nature, vol.83, issue.6506, pp.560-563, 1994. ,
DOI : 10.1038/349524a0
Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis, Arthritis Res Ther, vol.7, pp.1056-62, 2005. ,
Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors, Journal of Experimental Medicine, vol.175, issue.2, pp.323-332, 1992. ,
DOI : 10.1084/jem.175.2.323
Tumor necrosis factor et lymphotoxines, p.313, 1996. ,
Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors, J Immunol, vol.135, pp.2069-73, 1985. ,
A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia, Science, vol.229, issue.4716, pp.867-876, 1985. ,
DOI : 10.1126/science.3839597
CYTOKINES AND AUTOIMMUNITY, Nature Reviews Immunology, vol.15, issue.1, pp.37-45, 2002. ,
DOI : 10.1006/cyto.1999.0609
In Gériatrie : guide pratique, p.354, 1993. ,
Leptin produces anorexia and weight loss without inducing an acute phase response or protein wasting, Am J Physiol, vol.274, pp.1518-1543, 1998. ,
Cachexia: pathophysiology and clinical relevance ,
Impaired On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich Elements, Immunity, vol.10, issue.3, pp.387-398, 1999. ,
DOI : 10.1016/S1074-7613(00)80038-2
2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis & Rheumatism, vol.61, issue.Suppl 31, pp.2569-81, 2010. ,
DOI : 10.1002/art.27584
Elevated prolactin levels in patients with rheumatoid arthritis: association with disease activity and structural damage, Clin Exp Rheumatol, vol.28, pp.849-54, 2010. ,
Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis, The EMBO Journal, vol.10, pp.4025-4056, 1991. ,
The role of the synovial fibroblast in rheumatoid arthritis: cartilage destruction and the regulation of matrix metalloproteinases, Bull NYU Hosp Jt Dis, vol.64, pp.20-24, 2006. ,
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis, New England Journal of Medicine, vol.343, issue.22, pp.1594-602, 2000. ,
DOI : 10.1056/NEJM200011303432202
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study, Arthritis & Rheumatism, vol.39, issue.4, pp.1020-1050, 2005. ,
DOI : 10.1002/art.20982
New York clinical criteria for ankylosing spondylitis. A statistical evaluation., Annals of the Rheumatic Diseases, vol.32, issue.4, pp.354-63, 1973. ,
DOI : 10.1136/ard.32.4.354
The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis, Rheumatology, vol.44, issue.12, pp.1483-91, 2005. ,
DOI : 10.1093/rheumatology/kei047
Spondyloarthritis: state of the art and future perspectives, Annals of the Rheumatic Diseases, vol.69, issue.6, pp.949-54, 2010. ,
DOI : 10.1136/ard.2009.119529
Psoriatic arthritis: epidemiology, clinical features, course, and outcome, Annals of the Rheumatic Diseases, vol.64, issue.suppl_2, pp.14-17, 2005. ,
DOI : 10.1136/ard.2004.032482
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766874
Classification criteria for psoriatic arthritis: Development of new criteria from a large international study, Arthritis & Rheumatism, vol.59, issue.8, pp.2665-73, 2006. ,
DOI : 10.1002/art.21972
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies, Annals of the Rheumatic Diseases, vol.71, issue.1, pp.4-12, 2012. ,
DOI : 10.1136/annrheumdis-2011-200350
Le TNF-?? dans la physiopathologie du psoriasis, Annales de Dermatologie et de V??n??r??ologie, vol.133, issue.2, pp.174-80, 2006. ,
DOI : 10.1016/S0151-9638(06)70873-0
Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999), Gut, vol.53, issue.6, pp.843-851, 1988. ,
DOI : 10.1136/gut.2003.025346
Environmental risk factors in Crohn's disease and ulcerative colitis: an update, Gastroent??rologie Clinique et Biologique, vol.33, pp.145-57, 2009. ,
DOI : 10.1016/S0399-8320(09)73150-1
A meta-analysis of the role of smoking in inflammatory bowel disease, Digestive Diseases and Sciences, vol.284, issue.12, pp.1841-54, 1989. ,
DOI : 10.1007/BF01536701
Appendectomy and Protection against Ulcerative Colitis, New England Journal of Medicine, vol.344, issue.11, pp.808-822, 2001. ,
DOI : 10.1056/NEJM200103153441104
Genetic epidemiology in inflammatory bowel disease Dig Dis, pp.351-356, 1998. ,
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease, Nature, vol.411, issue.6837, pp.603-609, 2001. ,
DOI : 10.1038/35079114
Immunopathogen??se des maladies inflammatoires chroniques de l???intestin, m??decine/sciences, vol.26, issue.4, pp.405-415, 2010. ,
DOI : 10.1051/medsci/2010264405
Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease, Therapeutic Advances in Gastroenterology, vol.27, issue.1, pp.237-285, 2011. ,
DOI : 10.1016/S0002-9343(02)01383-9
Kinoids: a novel generation of specific immune therapy against cytokines, Med Sci, vol.24, pp.306-319, 2008. ,
Developpement et différenciation des lymphocytes B. In Atlas de poche d'immunologie, Ed Flammarion, vol.2008, pp.26-34 ,
Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy, Cancer Res, vol.45, pp.879-85, 1985. ,
Comparing antibody and small-molecule therapies for cancer, Nature Reviews Cancer, vol.23, issue.9, pp.714-741, 2006. ,
DOI : 10.1038/nrc1913
Lymphomes folliculaires et anticorps monoclonaux, Médecine thérapeutique, vol.5, pp.467-72, 1999. ,
Mécanismes d'action. In Mécanismes d'action des anticorps monoclonaux thérapeutiques. Ed Potentiel d'action, pp.14-28 ,
Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis, Current Medical Research and Opinion, vol.26, issue.10, pp.2287-300, 2010. ,
DOI : 10.1185/03007995.2010.507492
A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis, J Rheumatol, vol.32, pp.2303-2313, 2005. ,
Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels, Critical Care, vol.9, issue.5, p.20, 2005. ,
DOI : 10.1186/cc3798
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists, Journal of Pharmacology and Experimental Therapeutics, vol.301, issue.2, pp.418-444, 2002. ,
DOI : 10.1124/jpet.301.2.418
How does infliximab work in rheumatoid arthritis?, Arthritis Research, vol.4, issue.Suppl 2, pp.22-30, 2002. ,
DOI : 10.1186/ar549
Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis, Rheumatology, vol.41, issue.5, pp.484-493, 2002. ,
DOI : 10.1093/rheumatology/41.5.484
Etanercept, Annales de Dermatologie et de V??n??r??ologie, vol.132, issue.11, pp.861-76, 2005. ,
DOI : 10.1016/S0151-9638(05)79505-3
URL : https://hal.archives-ouvertes.fr/hal-00452839
Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies, Arthritis & Rheumatism, vol.52, issue.12, pp.3898-909, 2005. ,
DOI : 10.1002/art.21426
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial, Gastroenterology, vol.121, issue.5, pp.1088-94, 2001. ,
DOI : 10.1053/gast.2001.28674
Characterization of Noncovalent Complexes of Recombinant Human Monoclonal Antibody and Antigen Using Cation Exchange, Size Exclusion Chromatography, and BIAcore, Analytical Biochemistry, vol.299, issue.2, pp.119-148, 2001. ,
DOI : 10.1006/abio.2001.5380
Soluble Biomarkers of Cartilage and Bone Metabolism in Early Proof of Concept Trials in Psoriatic Arthritis: Effects of Adalimumab Versus Placebo, PLoS ONE, vol.35, issue.10, p.12556, 2010. ,
DOI : 10.1371/journal.pone.0012556.s007
Adalimumab in Crohn's disease, Biologics, vol.1, pp.355-65, 2007. ,
Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis, Clin Cosmet Investig Dermatol, vol.3, pp.49-58, 2010. ,
Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor ?? agents, Inflammatory Bowel Diseases, vol.13, issue.11, pp.1323-1355, 2007. ,
DOI : 10.1002/ibd.20225
Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety, Rheumatology, vol.50, issue.2, pp.261-70, 2011. ,
DOI : 10.1093/rheumatology/keq285
Certolizumab Pegol, mAbs, vol.58, issue.2, pp.137-184, 2010. ,
DOI : 10.1136/ard.2008.099218
Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents, British Journal of Pharmacology, vol.49, issue.2, pp.810-830, 2010. ,
DOI : 10.1111/j.1476-5381.2010.00702.x
The biology of TNF blockade, Autoimmunity Reviews, vol.2, issue.6, pp.346-57, 2003. ,
DOI : 10.1016/S1568-9972(03)00048-X
Infliximab in active early rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.63, issue.2, pp.149-55, 2004. ,
DOI : 10.1136/ard.2003.013961
Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis, J Rheumatol, vol.29, pp.1847-50, 2002. ,
Factors predicting responsiveness to anti-TNF?? therapy in patients with rheumatoid arthritis: using biotherapies rationally, Joint Bone Spine, vol.71, issue.2, pp.91-95, 2004. ,
DOI : 10.1016/j.jbspin.2003.10.007
Effective use of TNF antagonists, Arthritis Research & Therapy, vol.6, issue.Suppl 2, pp.24-30, 2004. ,
DOI : 10.1186/ar997
Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor ?? blockers can make sense, Annals of the Rheumatic Diseases, vol.62, issue.12, pp.1195-98, 2003. ,
DOI : 10.1136/ard.2003.009589
Switching tumour necrosis factor ?? antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period, Annals of the Rheumatic Diseases, vol.66, issue.10, pp.1393-1400, 2007. ,
DOI : 10.1136/ard.2007.073569
How Do We Manage Vaccinations in Patients with Inflammatory Bowel Disease?, Digestive Diseases, vol.27, issue.3, pp.370-374, 2009. ,
DOI : 10.1159/000228576
How tumour necrosis factor blockers interfere with tuberculosis immunity, Clinical & Experimental Immunology, vol.144, pp.1-9, 2010. ,
DOI : 10.1111/j.1365-2249.2010.04146.x
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940142
How to improve the safety of biologic therapy in Crohn's disease, J Physiol Pharmacol, vol.60, pp.67-70, 2009. ,
Demyelinating and neurologic events reported in association with tumor necrosis factor ? antagonism: By what mechanisms could tumor necrosis factor ? antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?, Arthritis & Rheumatism, vol.174, issue.9, pp.1977-83, 2001. ,
DOI : 10.1002/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6
Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register, Annals of the Rheumatic Diseases, vol.70, issue.5, pp.823-829, 2011. ,
DOI : 10.1136/ard.2010.140822
Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation, Annals of the Rheumatic Diseases, vol.66, issue.9, pp.1252-1256, 2007. ,
DOI : 10.1136/ard.2007.072397
Infliximab in the treatment of rheumatoid arthritis, Biologics: Targets & Therapy, vol.3, pp.183-91, 2009. ,
DOI : 10.2147/BTT.S3189
Anti-tumour necrosis factor-alpha therapy increase body weight in patients with chronic plaque psoriasis : a retrospective cohort study ,
Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor ?? treatment, Annals of the Rheumatic Diseases, vol.64, issue.8, pp.1137-1177, 2005. ,
DOI : 10.1136/ard.2004.028670
Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor-alpha treatment, J Rheumatol, vol.35, pp.855-61, 2008. ,
Randomized phase 2 trial of anti tumour necrosis factor therapy for cachexia in patients with early rheumatoid arthritis, Am J Clin Nutr, vol.84, pp.1463-72, 2006. ,
Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.69, issue.8, p.1571, 2010. ,
DOI : 10.1136/ard.2009.122424
Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis, Clinical Rheumatology, vol.27, issue.5, pp.455-61, 2012. ,
DOI : 10.1007/s10067-011-1863-6
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial, Annals of the Rheumatic Diseases, vol.64, issue.8, pp.1150-1157, 2005. ,
DOI : 10.1136/ard.2004.032268
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate, Annals of the Rheumatic Diseases, vol.68, issue.6, pp.954-60, 2009. ,
DOI : 10.1136/ard.2007.084459
Evaluation of a French version of the Bath Ankylosing Spondylitis Disease Activity Index in patients with spondyloarthropathy ,
A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index, J Rheumatol, vol.21, pp.2281-2286, 1994. ,
A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs, Joint Bone Spine, vol.78, pp.50-55, 2011. ,
Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men, New England Journal of Medicine, vol.364, issue.25, pp.2392-404, 2011. ,
DOI : 10.1056/NEJMoa1014296
Preliminary evidence for cachexia in patients with well-established ankylosing spondylitis, Rheumatology, vol.45, issue.11, pp.1385-1393, 2006. ,
DOI : 10.1093/rheumatology/kel127
Journey from cachexia to obesity by TNF, FASEB J, vol.11, pp.743-51, 1997. ,